Perseus Proteomics Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥94M | ¥100M | ¥120M | ¥136M |
| Gross Profit | ¥87M | ¥88M | ¥104M | ¥116M |
| Operating Income | -¥698M | -¥895M | -¥826M | -¥745M |
| Pretax Income | -¥698M | -¥895M | -¥826M | -¥745M |
| Net Income | -¥787M | -¥1,104M | -¥905M | -¥718M |
| EPS | -¥66.93 | -¥93.69 | -¥63.41 | -¥48.17 |
| Operating Margin | -740.72% | -891.15% | -686.55% | -549.75% |
| Balance Sheet | ||||
| Total Assets | ¥2,567M | ¥1,694M | ¥1,819M | ¥1,624M |
| Total Equity | ¥2,397M | ¥1,398M | ¥1,432M | ¥1,218M |
| Total Liabilities | ¥170M | ¥295M | ¥386M | ¥406M |
| Cash | ¥2,445M | ¥1,541M | ¥1,668M | ¥1,515M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 93.37% | 82.56% | 78.75% | 75.01% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥564M | -¥834M | -¥719M | -¥653M |
| Investing CF | -¥213M | -¥150M | -¥75M | -¥10M |
| Financing CF | -¥0M | ¥64M | ¥923M | ¥497M |
| Free CF | -¥735M | -¥993M | -¥795M | -¥663M |
| Efficiency | ||||
| ROE | -32.84% | -78.98% | -63.17% | -58.97% |
| ROA | -30.66% | -65.21% | -49.75% | -44.23% |
Latest IR Information
-
PPMX-T003: Results of clinical studies involving participants in a Phase I trial for polycythemia vera
Read more -
(Correction) Partial Revision of Items Concerning Business Plan and Growth Potential
Read more -
Matters Regarding Business Plan and Growth Potential
Read more -
Matters Regarding Business Plans and Growth Potential
Read more -
Notice Regarding the Large-Scale Exercise of Stock Acquisition Rights with Exercise Price Adjustment Clauses
Read more
Latest News (5 items)
Company Information
About
Perseus Proteomics Inc., a drug discovery biotech venture company, develops and sells antibody-based pharmaceuticals and research reagents for cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. Perseus Proteomics Inc. has a joint research agreement with ASKA Pharmaceutical Co., Ltd. for the development of new antibody drugs and therapeutic drugs for specific disease areas. Perseus Proteomics Inc. was incorporated in 2001 and is headquartered in Tokyo, Japan.
